Male Sex, B Symptoms, Bone Marrow Involvement, and Genetic Alterations as Predictive Factors in Diffuse Large B-Cell Lymphoma.

Matej Panjan, Vita Šetrajčič Dragoš, Gorana Gašljević, Srdjan Novaković, Barbara Jezeršek Novaković

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matej PanjanDivision of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0009-0002-0094-8355

Vita Šetrajčič DragošFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-7902-8879

Gorana GašljevićDepartment of Pathology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-8332-3627

Srdjan NovakovićFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-8888-4810

Barbara Jezeršek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-5063-7072

Funding

Slovenian Research and Innovation Agency P3-0321

6 · The paper itself

Abstract

Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) are not cured with first-line chemoimmunotherapy, resulting in poor prognosis. Schmitz et al. classified DLBCL into four prognostic genetic groups using whole-exome sequencing. We applied a simplified approach using a targeted next-generation sequencing assay (Archer FusionPlex Lymphoma Assay) to analyze samples from 105 patients-53 with a progression-free survival (PFS) < 2 years (the "Relapse group") and 52 with a PFS > 5 years (the "Remission group") following first-line systemic treatment. Patients were classified according to Schmitz et al. into the following categories: "MCD" (

Indexed as

Bone MarrowLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosisSex Factorsbone marrow involvementB symptomsDLBCLgenetic classificationpredictivesex

Identifiers

PMID40507898

DOI10.3390/ijms26115087

PMCPMC12154054

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.